Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects.

CONTEXT Zinc transporter 8 (ZnT8) is a newly discovered islet autoantigen in human type 1A diabetes (T1D). OBJECTIVE The objective was to document changes in ZnT8 autoantibody (ZnT8A) titer and prevalence after onset of disease in relationship to 65 kDa glutamate decarboxylase antibody (GADA) and islet cell antigen antibody (IA2A). DESIGN/PATIENTS Autoantibody radioimmunoprecipitation assays were performed on sera from three groups: 21 individuals monitored every 3 months from diagnosis for 2.5 yr; 61 individuals monitored at six monthly intervals for 5-12 yr; and a cross-sectional study of 424 patients with T1D of 20-57 yr duration. Circulating C-peptide was determined as an index of residual β-cell function. RESULTS ZnT8A titers declined exponentially from clinical onset of T1D with a t(1/2) ranging from 26 to 530 wk, similar to C-peptide (23-300 wk). Life-table analysis of antibody prevalence to 12 yr indicated that ZnT8A measured with either Arg325 or Trp325 probes persisted for a shorter interval than IA2A. Although prevalence of ZnT8A, IA2A, and GADA were comparable at disease onset (70.4 vs. 73.4 vs. 64%), only 6.7% of individuals remained ZnT8A positive after 25 yr compared with 19.5% for IA2A and 25.9% for GADA. Titers of ZnT8A and IA2A in seropositive individuals decreased progressively, whereas GADA remained elevated consistent with periodic reactivation of GADA humoral autoimmunity. CONCLUSIONS ZnT8 humoral autoreactivity declines rapidly in the first years after disease onset and is less persistent than IA2A or GADA in the longer term. ZnT8A determination may be a useful measure of therapeutic efficacy in the context of immune-based clinical interventions.

[1]  P. Bingley.  Clinical applications of diabetes antibody testing. , 2010, The Journal of clinical endocrinology and metabolism.

[2]  S. Bonner-Weir,et al.  Dimorphic histopathology of long-standing childhood-onset diabetes , 2010, Diabetologia.

[3]  Darrell M. Wilson,et al.  Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. , 2009, The New England journal of medicine.

[4]  J. Cambier,et al.  Change you can B(cell)eive in: recent progress confirms a critical role for B cells in type 1 diabetes , 2009, Current opinion in endocrinology, diabetes, and obesity.

[5]  W. Hagopian,et al.  Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. , 2009, Clinical immunology.

[6]  E. Bonifacio,et al.  Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk , 2009, Diabetologia.

[7]  G. Perozzi,et al.  Diabetes-linked zinc transporter ZnT8 is a homodimeric protein expressed by distinct rodent endocrine cell types in the pancreas and other glands. , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[8]  S. Richardson,et al.  Analysis of islet inflammation in human type 1 diabetes , 2009, Clinical and experimental immunology.

[9]  Johnny Ludvigsson,et al.  GAD treatment and insulin secretion in recent-onset type 1 diabetes. , 2008, The New England journal of medicine.

[10]  Association between anti-ZnT8 autoantibody specificities and SLC30A8 Arg325Trp variant in Japanese patients with type 1 diabetes , 2008, Diabetologia.

[11]  G. Eisenbarth,et al.  A Common Nonsynonymous Single Nucleotide Polymorphism in the SLC30A8 Gene Determines ZnT8 Autoantibody Specificity in Type 1 Diabetes , 2008, Diabetes.

[12]  M. Rowley,et al.  The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes , 2008, Proceedings of the National Academy of Sciences.

[13]  N. Breslow,et al.  Islet cell autoantibody levels after the diagnosis of young adult diabetic patients , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[14]  Marian Rewers,et al.  The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes , 2007, Proceedings of the National Academy of Sciences.

[15]  E. Bonifacio,et al.  GAD Autoantibody Affinity and Epitope Specificity Identify Distinct Immunization Profiles in Children at Risk for Type 1 Diabetes , 2007, Diabetes.

[16]  A. Carrascosa,et al.  Oxidative stress in childhood type 1 diabetes: Results from a study covering the first 20 years of evolution , 2007, Free radical research.

[17]  P. Bingley,et al.  Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. , 2007, Clinical immunology.

[18]  Å. Lernmark,et al.  Autoantibodies in diabetes. , 2005, Diabetes.

[19]  A. Favier,et al.  ZnT-8, A Pancreatic Beta-Cell-Specific Zinc Transporter , 2005, Biometals.

[20]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[21]  H. Ochs,et al.  Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174 , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  A. Favier,et al.  Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. , 2004, Diabetes.

[23]  A. Foulis,et al.  The pancreas in recent-onset Type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue , 1984, Diabetologia.

[24]  P. Fernlund,et al.  A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. , 2002, Diabetes.

[25]  D. Harlan,et al.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[26]  J. Krischer,et al.  Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1. , 2001, Diabetes.

[27]  Å. Lernmark,et al.  Glutamate decarboxylase (GAD) autoantibody epitope shift during the first year of type 1 diabetes. , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[28]  R. O’Brien,et al.  Molecular cloning of a pancreatic islet-specific glucose-6-phosphatase catalytic subunit-related protein. , 1999, Diabetes.

[29]  S. Kahn,et al.  Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study. , 1999, Diabetes.

[30]  E. Bonifacio,et al.  Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. , 1998, Journal of immunology.

[31]  M. Rewers,et al.  Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. , 1998, Diabetes.

[32]  J. Hutton,et al.  Molecular Cloning of Phogrin, a Protein-tyrosine Phosphatase Homologue Localized to Insulin Secretory Granule Membranes* , 1996, The Journal of Biological Chemistry.

[33]  H. Chase,et al.  Prediction of Type I Diabetes in First-Degree Relatives Using a Combination of Insulin, GAD, and ICA512bdc/IA-2 Autoantibodies , 1996, Diabetes.

[34]  E. Bonifacio,et al.  Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. , 1995, Journal of immunology.

[35]  L. Chatenoud,et al.  Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[37]  L. Groop,et al.  Immune responses to insulin in patients with insulin-dependent diabetes mellitus. , 1989, Autoimmunity.

[38]  A. Michael,et al.  Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. , 1985, Laboratory investigation; a journal of technical methods and pathology.